Professor, Pathology and Immunology, Washington University School of Medicine

Hematology

Charles works in the field of Hematology. He studied medicine at Vanderbilt University School of Medicine. Charles is also published. He has 69 publications published. The lastest publication: "Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority?' Doctor Charles S. Eby, MD is registered with Medicare and accepts Medicare payments.

Publications

---

• Triangulating Dynamic of Clinical Laboratory Testing.
• Clinical characteristics, prognostic factors and outcomes of adult patients With hemophagocytic lymphohistiocytosis.
• A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer.
• A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing.
• Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
• D-dimer: Simple Test, Tough Problems.
• Novel anticoagulants and laboratory testing.
• Warfarin Replacements: Good for Patients, Challenging for Laboratories.
• Pancytopenia after removal of copper from total parenteral nutrition.
• Safety concerns related to use of unapproved needles for accessing implantable Venous access devices.
• Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority?
• Clotting profiles and selected hematology of captive Speke's gazelles (Gazella spekei).
• Laryngeal epidermolysis bullosa acquisita requiring tracheostomy presenting With an acquired factor VIII coagulopathy.
• Antiphospholipid syndrome review.
• Improving influenza vaccination rates in the workplace: a randomized trial.
• The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative Venous thrombosis ...
• Venous thromboembolic Disease.
• Prediction and management of bleeding in cardiac surgery.
• CYP4F2 genetic variant alters required warfarin dose.
• Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients With HIT.
• Pathogenesis and management of bleeding and thrombosis in plasma Cell dyscrasias.
• Genetic-based dosing in orthopedic patients beginning warfarin therapy.
• Transfusion medicine service policies for recombinant factor VIIa administration.
• Gamma-glutamyl carboxylase and its influence on warfarin dose.
• A review of transfusion risks and optimal management of perioperative bleeding With cardiac surgery.
• Integration of genetic, clinical, and INR data to refine warfarin dosing.
• Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
• Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive.
• Use of pharmacogenetics to guide warfarin therapy.
• The pharmacogenetics of coumarin therapy.
• Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
• Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
• Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
• Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
• Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
• External quality assurance of antithrombin, protein C, and protein s assays: results of the College of American Pathologists proficiency testing program in thrombophilia.
• Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
• Blast flagging With the UniCel DxH 800 Coulter Cellular Analysis System.
• A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
• Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
• Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time.
• Variability of ferritin measurements in chronic kidney Disease; implications for iron management.
• Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.
• Evaluation of a prolonged prothrombin time.
• Bleeding and thrombosis risks in plasma Cell dyscrasias.
• Optimal initial dose adjustment of warfarin in orthopedic patients.
• Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program.
• Use of recombinant factor VIIa for hip surgery in a patient With factor-VII deficiency. A case report.
• External peer review quality assurance testing in von Willebrand Disease: the recent experience of the United States College of American Pathologists proficiency testi...
• Loss of factor VIII and von Willebrand factor activities during cold storage of whole blood is reversed by rewarming.
• Population variation in VKORC1 haplotype structure.
• Cold-dependent loss of factor VIII von Willebrand factor activities in citrated whole blood is reversed by rewarming.
• Ischemia-modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery.
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
• Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method.
• Laboratory assessment of oxygenation in methemoglobinemia.
• An evaluation of the utility of performing body fluid counts on the coulter LH 750.
• Recombinant activated factor VII for non-hemophiliac bleeding patients.
• The genetics of vitamin K antagonists.
• Pharmacogenetics and anticoagulant therapy.
• Lamellar body count in amniotic fluid: a comparative study of four different hematology analyzers.
• Long-term, low-intensity warfarin therapy for the prevention of recurrent Venous thromboembolism.
• Massive retroperitoneal pseudotumour in a patient with type 3 von Willebrand Disease.
• Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and Thrombosis.
• Heparin induced thrombocytopenia.
• A review of the Hypercoagulable state.
• Fatal outcome in a patient with autoimmune hemolytic Anemia associated with an IgM bithermic anti-ITP.
• Refractory immune hemolytic Anemia with a high thermal amplitude, low affinity IgG anti-Pra cold autoantibody.

Schools

---

• Vanderbilt University

• Strong Meml Hospital University Rochester

Procedures Preformed

---

• Plasmapheresis

Conditions Treated

---

• Anemia
• Antiphospholipid Syndrome (APS)
• Graft vs Host Disease
• Hematologic Abnormalities Associated With Pregnancy
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Education

---

• Washington University - Barnes-Jewish Hospital
• University of Rochester
• Vanderbilt University School of Medicine

Hospital

---

• Barnes-Jewish Hospital

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1457377764
Last Name Of The Provider	EBY
First Name Of The Provider	CHARLES
View All

Similar Doctors

---

	Dr. Matthew J. Ellis, MD
	Dr. Douglas R. Adkins, MD This Doctor is OpenDoctor Recommended.
	Dr. Adolphus C. Favors Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Zahid Kaleem, MD This Doctor is OpenDoctor Recommended.
	Dr. Andres S. Carden, MD This Doctor is OpenDoctor Recommended.
	Dr. Elaine M. Majerus, MD This Doctor is OpenDoctor Recommended.
	Dr. Nabeel R. Yaseen, MD This Doctor is OpenDoctor Recommended.
	Dr. Amanda Cashen, MD This Doctor is OpenDoctor Recommended.
	Dr. Burton M. Needles, MD This Doctor is OpenDoctor Recommended.
	Dr. Marianna B. Ruzinova, MD This Doctor is OpenDoctor Recommended.
	Dr. David D. Tran, MD This Doctor is OpenDoctor Recommended.
	Dr. Kian H. Lim, MD This Doctor is OpenDoctor Recommended.
	Dr. Tanner M. Johanns, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog